

# Alessandra Di Bacco

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8173406/publications.pdf>

Version: 2024-02-01

6  
papers

1,040  
citations

1477746

6  
h-index

1872312

6  
g-index

6  
all docs

6  
docs citations

6  
times ranked

1480  
citing authors

#	ARTICLE	IF	CITATIONS
1	Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration. <i>Clinical Cancer Research</i> , 2021, 27, 5195-5212.	3.2	26
2	câMYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomideâdexamethasone in myeloma. <i>European Journal of Haematology</i> , 2020, 105, 35-46.	1.1	8
3	Clinical benefit of ixazomib plus lenalidomideâdexamethasone in myeloma patients with nonâ€canonical NFâ€B pathway activation. <i>European Journal of Haematology</i> , 2020, 105, 274-285.	1.1	7
4	Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. <i>Blood</i> , 2017, 130, 2610-2618.	0.6	90
5	Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone <i>vs</i> . placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1. <i>Haematologica</i> , 2017, 102, 1767-1775.	1.7	48
6	Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2016, 374, 1621-1634.	13.9	861